Xellia Pharms Aps Company Profile

✉ Email this page to a colleague

XELLIA PHARMS APS has sixteen approved drugs.

There are seven US patents protecting XELLIA PHARMS APS drugs.

There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xellia Pharms Aps	TOBRAMYCIN SULFATE	tobramycin sulfate	INJECTABLE;INJECTION	205685-001	Sep 16, 2014	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	204107-002	Dec 28, 2015	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-001	Feb 15, 2019		RX	Yes	Yes	10,849,956	⤷ Try a Trial	Y			⤷ Try a Trial
Xellia Pharms Aps	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	205923-001	Jul 2, 2018		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-001	Feb 15, 2019		RX	Yes	Yes	10,039,804	⤷ Try a Trial	Y			⤷ Try a Trial
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-006	May 13, 2020		RX	Yes	Yes	10,039,804	⤷ Try a Trial	Y			⤷ Try a Trial
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-003	Feb 15, 2019		RX	Yes	Yes	10,849,956	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Brazil	112017009405	⤷ Try a Trial
Chile	2017001139	⤷ Try a Trial
Slovenia	3542812	⤷ Try a Trial
Eurasian Patent Organization	201790997	⤷ Try a Trial
European Patent Office	3675815	⤷ Try a Trial
Australia	2018322769	⤷ Try a Trial
Japan	2020531410	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0788511	SPC/GB08/036	United Kingdom	⤷ Try a Trial	PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
0620232	2001/029	Ireland	⤷ Try a Trial	PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
1115417	SZ 22/2006	Austria	⤷ Try a Trial	PRODUCT NAME: DAPTOMYCIN
0536515	SPC/GB06/033	United Kingdom	⤷ Try a Trial	PRODUCT NAME: TIGECYCLINE
1280520	300722	Netherlands	⤷ Try a Trial	PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
0788511	08C0028	France	⤷ Try a Trial	PRODUCT NAME: MICAFUNGINE; REGISTRATION NO/DATE: EU/1/08/448/001-002 20080425
1115417	SPC/GB06/024	United Kingdom	⤷ Try a Trial	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.